-
Aurinia Pharmaceuticals Inc (AUPH $15.39)
- $15.39 P/E (TTM): 7.71X Cap: $1.98B
- View AUPH Profile
- View Questions on AUPH
Detailed Quote
Questions on this company?
Become a Member
Company Profile
{tplLang.businessdescription | toLang tLang}
{ profileData.description }
{tplLang.details | toLang tLang}
{tplLang.ceo | toLang tLang}
{profileData.profile.details.ceo}
{tplLang.employees | toLang tLang}
{profileData.profile.details.employees | numeraljs '0,0'}
{tplLang.issuetype | toLang tLang}
{profileData.profile.details.issuetype | asIssueType}
{tplLang.industryclassifications | toLang tLang}
{tplLang.sector | toLang tLang}
{profileData.profile.classification.sector}
{tplLang.industry | toLang tLang}
{profileData.profile.classification.industry}
{tplLang.toolname| toLang tLang}
There is no {tplLang.toolname| toLang tLang} currently available for
{data.symbolstring}.
Interactive Chart
Key Ratios
Earnings
Analyst Recommendations
5i Recent Questions
-
Teradyne Inc. (TER $343.47)
- $343.47 P/E (TTM): 109.55X Cap: $47.95B
- View TER Profile
- View Questions on TER
-
Globus Medical Inc. Class A (GMED $90.18)
- $90.18 P/E (TTM): 23.78X Cap: $11.91B
- View GMED Profile
- View Questions on GMED
-
Amkor Technology Inc. (AMKR $69.75)
- $69.75 P/E (TTM): 47.26X Cap: $17.50B
- View AMKR Profile
- View Questions on AMKR
-
Innovative Solutions and Support Inc. (ISSC $22.00)
- $22.00 P/E (TTM): 19.11X Cap: $353M
- View ISSC Profile
- View Questions on ISSC
-
Spero Therapeutics Inc. (SPRO $2.51)
- $2.51 P/E (TTM): 17.8X Cap: $158M
- View SPRO Profile
- View Questions on SPRO
-
Puma Biotechnology Inc (PBYI $7.51)
- $7.51 P/E (TTM): 12.36X Cap: $383M
- View PBYI Profile
- View Questions on PBYI
-
PDF Solutions Inc. (PDFS $42.85)
- $42.85 Cap: $1.59B
- View PDFS Profile
- View Questions on PDFS
-
Allegro MicroSystems Inc. (ALGM $48.50)
- $48.50 Cap: $8.16B
- View ALGM Profile
- View Questions on ALGM
-
Tattooed Chef Inc. (TTCF)
- Cap: $24M
- View TTCF Profile
- View Questions on TTCF
-
iRadimed Corporation (IRMD $83.44)
- $83.44 P/E (TTM): 48.28X Cap: $1.13B
- View IRMD Profile
- View Questions on IRMD
-
Aurinia Pharmaceuticals Inc (AUPH $15.39)
- $15.39 P/E (TTM): 7.71X Cap: $1.98B
- View AUPH Profile
- View Questions on AUPH
Q: How would you rank the above companies from 1 to 10 from an buyer's point of view?
-
Aurinia Pharmaceuticals Inc (AUPH $15.39)
- $15.39 P/E (TTM): 7.71X Cap: $1.98B
- View AUPH Profile
- View Questions on AUPH
Q: Yesterday a FDA official gave very negative opinions and comments on Aurinia pharmaceuticals then removed them at end of trading day. Volume went up to almost 8million shares and stock was crushed. This stinks to high heaven. What do you folks think of this and will there be law suits maybe officials checking into short covering etc. Also how long will the cloud remain over this stock it was just taking off when all this happened.
-
Aurinia Pharmaceuticals Inc (AUPH $15.39)
- $15.39 P/E (TTM): 7.71X Cap: $1.98B
- View AUPH Profile
- View Questions on AUPH
Q: This stock is up 50% in less than a month and is at a 52 week high it also will be making about 270 million going forward this year. They get to keep 90% of that. My simple math has them at a P/E of 6.4 on a forward basis if they don’t overachieve. There drug is getting traction into the hospitals and with the doctors due to its drug profile.
Aurina has another drug in the pipeline going into phase two that looks good and I hope they go after rheumatoid arthritis. To me everything looks good here. This is my fun stock to stop me from becoming too bored and is finally becoming exciting.
What do you folks think is going on here regarding the big move in the stock price and where it could go. Looks like the existing drug revenue tops out an around 600 million annually.
Aurina has another drug in the pipeline going into phase two that looks good and I hope they go after rheumatoid arthritis. To me everything looks good here. This is my fun stock to stop me from becoming too bored and is finally becoming exciting.
What do you folks think is going on here regarding the big move in the stock price and where it could go. Looks like the existing drug revenue tops out an around 600 million annually.
Insiders
Share Information
SEC Filings
News and Media